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Abstract
Purpose Clinical trials in glioma patients with neurocog-
nitive deficits face challenges due to lacking or unreliable
patient self-reports on their health-related quality of life
(HRQOL). Patient–proxy data could help solve this issue.
We determined whether patient–proxy concordance levels
were affected by patients’ neurocognitive functioning.
Methods Patient and patient-by-proxy HRQOL ratings
were assessed via SF-36 and EORTC QLQ-BN20,
respectively, in 246 patients. Data on neurocognitive
functioning were collected on a subgroup of 195 patients.
Patient–proxy agreement was measured using the Bland–
Altman limit of agreement, the mean difference, the con-
cordance correlation coefficient (CCC), and the percentage
difference (PD, ±0, 5, or 10 points). We defined patients to
be cognitively impaired (n = 66) or cognitively intact
(n = 129) based on their neurocognitive performance.
Results Patients rated their physical function and general
health to be better than their proxies did, while at the same
time, patients reported more visual disorders, communi-
cation deficits, itchy skin, and problems with bladder
control. The cognitively impaired subgroup reported poorer
physical functioning, more visual disorders, headaches,
itchy skin, and issues with bladder control. In the cogni-
tively intact group, no statistical significant differences
were observed between patients and proxies. Not surpris-
ingly, Bland–Altman plots revealed a high agreement
between the patient and patient-by-proxy rating in all
HRQOL domains ranging from 95 to 99 %. The CCC was
fairly high in all HRQOL domains (0.37–0.80), and the
percentage of perfect agreement (PD ± 0) ranged from 8.5
to 76.8 %. In the cognitively impaired patients, the mean
difference between patients and proxies was overall larger,
and accordingly, agreement based on Bland–Altman plots
was lower.
Conclusions The level of agreement between patient and
patient-by-proxy ratings of low-grade glioma patients’
HRQOL is generally high. However, patient–proxy
agreement is lower in patients with neurocognitive deficits
than in patients without neurocognitive deficits.
Keywords Brain tumor  Health-related quality of life 
Proxy ratings  Neurocognitive deficits
Introduction
Health-related quality of life (HRQOL) has become an
important secondary outcome measure in clinical trials of
glioma patients [1, 2] with all European Organization for
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Research and Treatment of Cancer (EORTC) brain tumor
clinical trials and most trials by other cancer groups now
incorporating HRQOL. HRQOL is an important comple-
ment to conventional outcome parameters such as time to
tumor progression, overall and progression-free survival,
and radiological response might be inadequate or less rel-
evant for meaningful evaluation of this type of treatment
[3]. HRQOL in glioma patients is influenced by both
tumor- and treatment-related factors [4, 5] with seizures
and antiepileptic drugs [6], fatigue [7], anxiety and
depression [8], and neurocognitive deficits [9, 10] affecting
HRQOL in particular. Apart from negatively affecting
HRQOL, neurocognitive deficits may also hamper ade-
quate patient self-reports, as patients’ neurocognitive def-
icits may render HRQOL patient-reported outcomes
through questionnaires unreliable [11]. Exclusion of these
patients at the lower end of the neurocognitive spectrum
from analyses obviously introduces undesirable bias in the
evaluation of patients’ HRQOL during experimental
treatments. Moreover, cognitively impaired patients may
be less compliant regarding questionnaire-based HRQOL
monitoring, thereby introducing another source of bias.
The incorporation of HRQOL estimates of the partner
or another close relative or friend (denominated as
‘proxy’) might solve this problem to a large extent. Pre-
vious reports indicate that high-grade glioma patient- and
proxy-reported HRQOL have a high level of concordance
as long as the patient shows no signs of decline in neu-
rocognitive function [12, 13], but differences, particularly
in mood-related issues, increase when neurocognitive
functioning decreases [13, 14]. While HRQOL is by
definition subjective, and it is typically measured with
self-reports, it has been suggested that substituting proxy
ratings when a patient’s self-report is absent or unreliable
should be considered [15]. When differences between
patient- and proxy-reported HRQOL ratings develop in
the course of the disease (presumably at the time, decline
in neurocognitive function becomes an issue), proxy-re-
ported instead of patient-reported HRQOL ratings might
be regarded as the most reliable source of information on
patients’ HRQOL.
Previous studies reported that low observed correlations
between patient- and patient-by-proxy-reported outcomes
might be explained by methodological weaknesses such as
small sample size, suboptimal reliability, and score vari-
ability [13, 14]. This was supported by Bland and Altman,
who stated that a single measure such as a correlation
coefficient may not be sufficient to summarize agreement
adequately [16, 17]. In the present study, by using a wide
range of statistical measures of agreement, we investigated
patient–proxy HRQOL agreement in a large sample of low-
grade glioma (LGG) patients, both with intact and with
impaired neurocognitive functioning. The cohort used in
this analysis is unique because of the extensive neurocog-
nitive test battery incorporated.
The aim of the present study is to investigate the
agreement between patient and patient-by-proxy ratings of
HRQOL and to investigate whether the level of neu-
rocognitive functioning influences the level of patient–
proxy concordance. We hypothesized that (1) concordance
levels are relatively high on mental and physical func-
tioning in cognitively intact patients, and (2) there is a
decrease in mental functioning in cognitively impaired
patients, with proxies being more negative on patients’
HRQOL.
Patients and methods
For this cross-sectional study, we recruited low-grade
glioma (LGG) patients who were disease-free for at least
one year following diagnosis and primary treatment, and
their proxies. Patients were recruited from neurosurgical
centers throughout the Netherlands between February,
1997 and January, 2000. Eligibility was checked with the
general practitioner and by a case-note review. Low-grade
glioma was classified histologically as astrocytoma,
oligodendroglioma, or oligoastrocytoma. Patients were
excluded if they used corticosteroids (because use of cor-
ticosteroids might indicate non-stable disease), did not
have a basic proficiency in the Dutch language, or were
unable to communicate adequately. All patients provided
written informed consent to be involved on the study, and
ethics approvals of the study protocol were obtained from
the medical ethics committees of the institutions. The
details of the study conduct and clinical outcome have been
reported elsewhere [18].
Health-related quality-of-life assessments
HRQOL was assessed using the MOS SF-36 Short-Form
Health Survey (SF-36) [19, 20] in conjunction with the
European Organization for Research and Treatment of
Cancer Brain Cancer module (QLQ-BN20) [21] to assess
additional health problems associated specifically with
glioma and its treatment. The MOS SF-36 is a self-report
questionnaire developed in the USA as a part of a large,
national study of the effect of various forms of health care
delivery on patients’ health status and quality of life [22]. It
is composed of 36 items, organized into eight multi-item
scales assessing: (1) physical functioning; (2) bodily pain;
(3) role limitations due to physical health problems; (4)
role limitations due to personal or emotional problems; (5)
emotional well-being; (6) social functioning; (7)
energy/fatigue; and (8) general health perceptions. Sum-
mary component scores for physical health (PCS) and
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mental health (MCS) were also calculated. Higher scores
indicate better health. The questionnaire has excellent
reliability and validity when employed with diverse patient
populations [23, 24]. The SF-36 also has exhibited good
validity and reliability (Cronbach’s alpha = 0.84) when
employed among Dutch cancer patients [25].
The QLQ-BN20, where higher scores indicate more
symptoms, is composed of 20 items, organized into five
subscales assessing future uncertainty, visual disorder,
motor dysfunction, communication deficit, and emotional
distress. The remaining seven items assess other disease
symptoms, and side effects of treatment found to be
prevalent among patients with brain tumors, including
headaches, seizures, drowsiness, hair loss, itching, weak-
ness in the legs, and lack of bladder control. The QLQ-
BN20 has robust psychometric properties that result from
rigorous testing and the development of their use in several
international clinical cancer trials [26]. The SF-36 and
QLQ-BN20 were completed by (1) the patient; (2) the
partner, providing a ‘proxy’ rating of the patients’ HRQOL,
i.e., patient-by-proxy. Based on the objective outlined in
the introduction, we will limit our analysis of agreement to
SF-36 and QLQ-BN20 questionnaires completed by the
patient and the partner as a proxy.
Neurocognitive assessments
Neurocognitive functioning refers to an individual’s
ability to perceive, store, retrieve, and use sensory and
perceptual information from the environment and past
experience, and to such mental activities as plans and
strategies [18]. A disability score was calculated for every
patient; neurocognitive test scores were converted to
z-scores, with the mean scores of the healthy controls as a
reference. The lower 5th percentile of the healthy controls
was used as a cut-off score for cognitive disability [27].
To calculate an overall disability score for every patient,
we counted the number of tests on which the patient
scored below this cut-off. Application of this algorithm to
our data showed that a glioma patient was judged to have
a neurocognitive disability if he or she had deviant scores
for at least 4 of the 20 tests. Only tests for which healthy
controls could be individually matched with LGG patients
for age, sex, and educational level were used for this
analysis. Unlike, for instance, research concerning
patients with Alzheimer’s disease (AD), there is no con-
sensus on what represents a ‘true’ drop in neurocognitive
functioning in brain tumor patients. By applying this
strict, clinically based cut-off, we assume that patients
with neurocognitive disability will experience limitations
in their daily life functioning. Detailed information about
the standard tests used to assess cognitive status is shown
in Table 1.
Functional/performance status
Patient’s performance status was assessed with the
Karnofsky performance status scale (KPS). [28, 29] This
physician-rated scale is used widely as an outcome mea-
sure in cancer clinical studies.
The capacity to carry out activities of daily living (ADL)
was assessed with the Barthel Index [30]. This index
consists of 10 items assessing: continence of bowels and
bladder, grooming, toilet use, feeding, transfer, mobility,
dressing, climbing stairs, and bathing. The items are
ordered in ascending degree of difficulty. It has proven to
be a reliable and valid instrument for assessing disability in
basic activities of daily living (ADL) and mobility and has
been used primarily with stroke patients.
Neurological functioning was rated with the neurologi-
cal functional status scale developed by Order et al. [31].
Scores range from 1 to 4, with high scores for strong
neurological function.
Statistical analysis
The raw scores from both the SF-36 and QLQ-BN20 were
transformed to a linear scale that ranged from 0 to 100, in
which a higher score represents a higher level of func-
tioning or a worse level of symptoms [32, 33]. The fol-
lowing techniques were used to measure the agreement
between the patient and the patient-by-proxy HRQOL
scores. The mean differences (patient-by-proxy minus
patient) on the SF-36 and QLQ-BN20 were summarized as
means and SD. Wilcoxon signed-rank test was used to test
the differences between patient and patient-by-proxy
scores. The proportion of subjects whose difference
between patient and patient-by-proxy scores was within
±0, 5 and 10 units [34, 35] was summarized. A difference
within ±0 was considered as perfect agreement. Bland–
Altman limits of agreement (LA) [16, 36–39] were created
to measure the agreement between patient and patient-by-
proxy scores and to demonstrate the extent of rater dis-
agreement across the range of a scale (i.e., to evaluate the
magnitude of disagreement, the identification of outliers,
and the observation of any bias) for each method of mea-
surement. The Bland–Altman method depicts the mean
difference between two methods of measurement (the
‘bias’), and 95 % limits of agreement (prediction interval)
as the mean difference (2 SD) [or more precisely (1.96
SD)]. It is the pattern of the data points that identify
agreement, types of bias and outliers. It is expected that the
95 % limits include 95 % of the data point differences
between the two measurements, i.e., about 95 % of the
points should lie with the interval. Lin’s concordance
correlation coefficient (CCC) [40, 41] was also computed
for patient and patient-by-proxy scores.
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To investigate the effect of neurocognitive function on
the patient–proxy agreement, we defined patients as being
cognitively impaired (n = 66) or cognitively intact
(n = 129) based on their neuropsychological performance.
We then assessed the level of agreement via LA for PCS
and MCS and mean difference for both the SF-36 and
QLQ-BN20 scales.
Results
In this nationwide study [18] into HRQOL and neurocog-
nitive functioning in low-grade glioma patients, we
recruited 281 adult patients with supratentorial low-grade
gliomas who were asked to complete the SF-36 and QLQ-
BN20 scales. Their proxies were asked to complete the
questionnaire on the patient’s SF-36 and QLQ-BN20; 35 of
the 281 glioma patients (12.5 %) had no patient-by-proxy
assessment and were thus excluded from the analyses.
Forty-four of the 239 glioma patients (18 %) who met the
inclusion criteria and who were asked to participate in the
neurocognitive part of the study declined to participate; the
main reasons being that participation was too burdensome,
or that they were reluctant to be confronted with what they
believed to be a cured illness. Neurocognitive data were
available for 195 patients (87.5 %), of whom 104 (53 %)
had received radiotherapy 1–22 years previously. Ninety-
three percent of glioma patients were tested at home; the
remainder were tested in the hospital. The clinical char-
acteristics of the LGG patients have been described
previously [18]. Briefly, Table 2 shows the sociodemo-
graphic and clinical characteristics of the LGG patients.
The mean age was 42 years, with the majority being men
(62 %). The histological diagnosis was astrocytoma
(71 %), oligodendroglioma (22 %), and oligoastrocytoma
(7 %). Patients’ performance status (KPS), their capacity to
carry out activities of daily living (Barthel), and neuro-
logical functioning (Order) reached near-optimal levels.
Agreement between patient and patient-by-proxy
measurements
Table 3 summarizes the HRQOL measures for both the
patients and patient-by-proxy (n = 246). Patients and
patient-by-proxy scored similar on all scales, except for the
SF-36 scale physical functioning and general health, and
the QLQ-BN20 subscales visual disorder and communi-
cation deficit, and the single-item itchy skin, with patients
reporting worse level of symptoms and better level of
functioning than their proxies. There was also a statistically
significant difference in the SF-36 PCS (-1.30; p = 0.02)
with patients reporting a higher score than their proxies.
The difference between patients and patient-by-proxy was
calculated, and the proportion within ±0 (perfect agree-
ment), 5, and 10 units was summarized with a range of
8.54 % (general health and mental health) to 76.83 % (hair
loss), 19.51 % (vitality rating) to 84.55 % (hair loss), and
40.65 % (general health) to 86.59 % (role-emotional),
respectively. The Bland–Altman limit of agreement (LA)
for the PCS and MCS and each of the HRQOL measures
Table 1 Neuropsychological tests and corresponding cognitive domains
Intelligence
Dutch adult reading test [30] Estimates premorbid intellectual functioning on the
basis of verbal ability
Perception and psychomotor speed
Line bisection test [31] Measures unilateral neglect, which is usually a sequel
of massive right hemisphere lesions
Facial recognition test [31] Detects impairment in the discrimination of faces, a
disorder associated with right hemisphere lesions
Judgment of line orientation test [31] A test of visuospatial judgment, also detects right hemisphere dysfunction
Letter-digit substitution test (LDST) [31] Measures psychomotor speed that is relatively
unaffected by a decline in intellectual ability
Memory
Visual verbal learning test (VVLT) [31] Examines several aspects of verbal learning, organization, and memory
Working memory task (WMT) [31] Measures the speed of memory processes
Attention and executive function
Stroop color-word test (SCWT) [31] Examines attention, mental speed, and mental control
Categoric word fluency task [31] Measures the speed and flexibility of verbal thought processes
Concept shifting test (CST) [32] Measures attention, visual searching, mental-processing speed,
and the ability to mentally control simultaneous stimulus patterns
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revealed a fairly high agreement between the patient and
patient-by-proxy rating in all HRQOL domains. The best
agreement between the patient and patient-by-proxy for the
SF-36 was for role-physical (points within the 95 % limit
of agreement = 99.15 %, 95 % LA; -20.49–19.00) and
role-emotional (99.15 %; -16.86–16.93), and for the
QLQ-BN20, hair loss (98.68 %; -36.04–34.87) and blad-
der control (98.24 %; -43.68–38.98). A slightly poorer
agreement was observed for the PCS (93.06 %;
-13.63–11.03) and physical functioning (94.98 %;
-31.52–25.86). Bland–Altman plots are shown for SF-36
role-physical (see Supplementary Figure S1), role-emo-
tional (see Supplementary Figure S2), and physical func-
tioning (see Supplementary Figure S3) to depict the extent
of rater agreement across a scale range. Finally, Lin’s CCC
was calculated for each HRQOL measure (Table 3). Lin’s
CCC showed a moderate-to-strong relationship ranging
from r = 0.37 (weakness in the legs) to r = 0.80 (physical
functioning), with 79 % of the measurements greater than
0.5 [42]. The CCC for PCS was (r = 0.69) and MCS was
(r = 0.55).
Impact of neurocognitive deficits on patient
and patient-by-proxy agreement
The impact of neurocognitive deficits on the agreement
between patient and patient-by-proxy HRQOL scores was
also examined. Out of the 195 patients who had data on
neurocognitive functioning, 66 (33.85 %) patients were
cognitively impaired according to our definition. The mean
difference in the cognitively intact patient group was
overall smaller as compared to the cognitively impaired
patients (Tables 4, 5), and the Bland–Altman LA was also
higher in the cognitively intact group. In the cognitively
impaired group, large and statistically significant differ-
ences were observed for the QLQ-BN20 visual disorder
(mean difference = -7.80; p = 0.001), headaches (-5.95;
p = 0.02), itchy skin (-7.02; p = 0.02), and bladder
control (-8.77; p = 0.02), indicating that cognitively
impaired patients and their proxies did not agree on these
scales. The difference for SF-36 physical functioning was
borderline significant (-4.10; p = 0.05) (Table 4). As
shown in Table 5, there were no statistically significant
differences in any of the HRQOL scales in the cognitively
intact patient group. The largest difference was observed in
the QLQ-BN20 headache (5.50; p = 0.06) with borderline
significance. The LA for PCS and MCS are shown in
Figs. 1 and 2 to illustrate the extent of rater agreement
across the scale range in the summarized SF-36 scales.
Discussion
Measuring neurocognitive functioning is essential in brain
tumor patients, because this may strongly influence their
HRQOL and also patient–proxy concordance levels.
Although the patient is the primary source of information
when measuring HRQOL, the information collected from
patients with glioma may be unreliable, especially in those
patients who are experiencing significant neurocognitive
deterioration [14]. It is recommended to obtain proxy (i.e.,
caregivers) HRQOL ratings alongside a patient’s own self-
report and to consider substituting patient-by-proxy ratings
when a patient’s self-report is absent [43]. The original
analysis of this study showed that glioma patients reported
lower levels of self-reported neurocognitive functioning as
measured by the MOS scales than did the healthy controls:
47.80 versus 82.40, respectively [18].
In the present study, we found that there was overall a
high agreement between the patient and patient-by-proxy
rating of LGG patients HRQOL in most subscales of the
SF-36 and QLQ-BN20. The only statistically significant
differences were observed in SF-36 physical functioning
and general health and QLQ-BN20 visual disorder, com-
munication deficit, and itchy skin. Noticeable mean
Table 2 Sociodemographic and clinical characteristics
Characteristics LGG patients (n = 195)
Age in years, mean (SD) 40.79 (11.62)
Male sex, n (%) 120 (61.54 %)
Level of education, mean (SD) 4.16 (2.09)
Radiotherapy, n (%)
Yes 104 (53.33 %)
No 91 (46.67 %)
Premorbid intelligence, mean (SD)
Dutch adult reading test 99.94 (10.78)
Histological diagnosis, n (%)
Astrocytoma 139 (71.28 %)
Oligodendroglioma 43 (22.05 %)
Oligoastrocytoma 13 (6.67 %)
Tumor lateralization, n (%)
Left-sided 97 (49.74 %)
Right-sided 91 (46.67 %)
Bilateral 7 (3.59 %)
Neurosurgical intervention, n (%)
Biopsy 84 (43.08 %)
Resection 111 (56.92 %)
Epileptic seizures, n (%) 167 (85.64 %)
Antiepileptic drug use, n (%) 139 (71.28 %)
Years since diagnosis, mean (SD) 5.62 (3.66)
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differences were observed in the cognitively impaired
group especially on the QLQ-BN20 scores regarding visual
disorder, headaches, itchy skin, and bladder control. A
noticeable difference in the cognitively intact patient group
was only observed in the QLQ-BN20 headaches score. The
difference between patient and patient-by-proxy ratings
found in the whole group of patients could be due to the
cognitively impaired patients. Although all of the differ-
ences were statistically significant, they were less than the
10 points generally accepted as clinically meaningful.
However, some scores may have represented small,
potentially noticeable changes in the range of 5–10 points
[44] which could be important to the individual patient and
warrant clinical attention.
The Bland–Altman plot revealed a high agreement
between the patient and patient-by-proxy rating of
HRQOL, where about 95 % of the differences between the
two measurements were within the 95 % limits of agree-
ment (prediction interval) except for SF-36 physical func-
tioning scale and the summary component score for
physical functioning (PCS). However, the limit of agree-
ment was lower in the cognitively impaired patient group.
One of the reasons for this lower agreement may be that
patients, who are aware of the fact that their cognitive
functions are severely affected, regard their HRQOL as
poor (which is also the case in AD patients). Proxies may
not fully appreciate the emotions which accompany decline
of intellectual functioning.
It is important that the extent of agreement across the
range of measurement be stable between the patient and
patient-by-proxy [39]. Our findings showed that the
agreement was poor for the central section of the scales






















CCC (95 % CI) p valuesb
PCS 44.11 45.57 -1.30 (6.16) 93.06 (-13.63–11.03) – 76.42 93.09 0.69 (0.62–0.76) 0.02
MCS 41.89 42.01 0.22 (7.68) 97.11 (-15.14–15.58) – 65.85 87.40 0.55 (0.44–0.65) 0.83
Physical functioning 80.08 83.44 -2.83 (14.35) 94.98 (-31.52–25.86) 32.93 67.07 77.64 0.80 (0.76–0.85) 0.01
Mental health 70.21 71.83 -1.06 (18.12) 95.68 (-37.30–35.17) 8.54 45.53 63.01 0.52 (0.42–0.62) 0.55
General health 56.08 60.16 -3.47 (22.03) 97.46 (-47.53–40.60) 8.54 26.02 40.65 0.54 (0.45–0.63) 0.04
Role-physical 15.29 16.20 -0.75 (9.87) 99.15 (-20.49–19.00) 43.90 47.97 74.39 0.52 (0.43–0.61) 0.29
Bodily pain 79.16 81.13 -1.72 (22.01) 96.68 (-45.74–42.29) 41.06 44.72 51.63 0.57 (0.49–0.66) 0.34
Vitality rating 58.94 61.54 -2.53 (20.74) 95.74 (-44.01–38.98) 10.57 19.51 41.46 0.58 (0.50–0.67) 0.14
Role-emotional 19.02 18.93 0.03 (8.45) 99.15 (-16.86–16.93) 62.60 66.67 86.59 0.58 (0.50–0.66) 0.76
Social functioning 78.41 77.35 1.17 (22.08) 96.69 (-42.99–45.33) 39.43 41.06 41.06 0.56 (0.48–0.65) 0.34
EORTC Brain Cancer module QLQ-BN20c
Future uncertainty 25.52 23.47 2.11 (24.69) 95.18 (-47.28–51.49) 22.76 30.08 54.88 0.47 (0.38–0.57) 0.49
Visual disorder 11.28 14.08 -2.50 (19.22) 96.92 (-40.93–35.94) 45.93 53.66 53.66 0.50 (0.40–0.60) 0.04
Motor dysfunction 14.36 13.79 0.66 (18.05) 95.63 (-35.45–36.76) 47.56 54.47 54.88 0.56 (0.48–0.65) 0.48
Communication
deficit
20.86 22.96 -2.26 (23.98) 95.67 (-50.22–45.70) 74.80 82.52 82.52 0.53 (0.44–0.62) 0.03
Headaches 26.75 24.620 1.90 (26.39) 97.37 (-50.22–54.68) 57.72 65.04 65.04 0.61 (0.53–0.69) 0.50
Seizures 18.03 18.63 0.15 (23.41) 97.79 (-46.68–46.97) 68.29 76.42 76.42 0.67 (0.60–0.74) 0.88
Drowsiness 23.79 21.72 1.60 (28.65) 97.82 (-55.71–58.91) 52.85 59.76 59.76 0.47 (0.37–0.57) 0.46
Hair loss 6.01 6.94 -0.59 (17.73) 98.68 (-36.04–34.87) 76.83 84.55 84.55 0.49 (0.39–0.59) 0.50
Itchy skin 9.05 11.67 -2.95 (20.39) 98.23 (-43.74–37.84) 71.95 80.08 80.08 0.59 (0.51–0.67) 0.04
Weakness legs 5.80 6.78 -1.19 (20.38) 98.22 (-41.94–39.57) 75.61 84.15 84.15 0.37 (0.25–0.48) 0.35
Bladder control 8.44 10.56 -2.35 (20.67) 98.24 (-43.68–38.98) 74.80 82.52 82.52 0.56 (0.47–0.65) 0.06
PCS Physical component summary
MCS Mental component summary
CCC Concordance correlation coefficient
a Higher scores indicate better health
b Wilcoxon signed-rank test
c Higher scores indicate more of the symptoms
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(supplementary Figures). This was also shown by Gie-
singer et al. [12] who likewise stated that the possible
discrepancies (i.e., ‘bias’) between the patient and patient-
by-proxy are reduced by the limited range scale. The cur-
rent study found a moderate-to-strong correlation between
patient and patient-by-proxy scores (CCCs[0.5 for 79 %
of the measurements). It is thus much easier to demonstrate
agreement when a patient is experiencing either very few
or many symptoms, but as the number of symptoms moves
closer to 50–50 distribution, patient–proxy agreement
decreases.
Regarding the methodology, our results compare quite
favorably with other studies that have examined proxy
ratings for general cancer patients [13, 45], brain cancer
patients [12, 13], epilepsy patients [46], and stroke patients
[47]. For example, a previous study in HRQOL of brain
cancer patients and their proxy raters showed that intra-
class correlations (ICCs) were greater than 0.5 for 77 %
multi-item measures and 38 % of single-item measures
[13]. However, in this previous study [13], the authors did
not implement an extensive testing of patients’ neurocog-
nitive functioning, which we did in this study. Also, the use
of sound statistical techniques such as the Bland–Altman
limits of agreement [16, 36–39], which are straightforward
and easy to interpret, enabled us to investigate any possible
relationship between the measurement error and the true
value. Furthermore, our study has a large sample size and a
homogeneous patient population.
Patient-by-proxy ratings may resolve compliance issues
when assessing HRQOL in glioma patients with intact
neurocognitive function. Probably more important in
glioma patients than in any other cancer patient population,
but comparable to other patients with neurological diseases
associated with neurocognitive decline (e.g., Mild Cogni-
tive Impairment and AD), patient-by-proxy ratings might
also be helpful when patients cognitively deteriorate and
lack the ability and insight to accurately interpret and
understand the HRQOL measures. In the current study,
although there was a good agreement between patient and
patient-by-proxy ratings for the whole sample, there was
less agreement between patient and patient-by-proxy rat-
ings for those patients with impaired neurocognitive
function compared to those patients with unimpaired neu-
rocognitive function. While patient and patient-by-proxy
ratings in such situations should not be regarded a priori as
incorrect [46], insight is needed into the sources of varia-
tion between patient and proxy ratings. In a small study
that compared HRQOL ratings from proxies and patients
Table 4 Mean difference
(patient-by-proxy minus
patient) cognitively impaired
patients (n = 66)
SF-36 Mean proxy Mean patient Mean difference
Mean (SD) p valuesa
Physical component summary 40.46 42.26 -1.73 (7.10) 0.07
Mental component summary 40.52 39.75 1.41 (7.90) 0.26
Physical functioning 68.64 74.03 -4.10 (17.11) 0.05
Mental health 67.22 65.31 3.06 (17.30) 0.26
General health 47.32 51.77 -3.80 (22.69) 0.23
Role-physical 10.75 12.12 -1.29 (10.27) 0.33
Bodily pain 72.62 71.10 1.52 (21.76) 0.30
Vitality 50.38 52.34 -2.57 (20.41) 0.30
Role-emotional 15.70 15.17 0.37 (10.03) 0.63
Social functioning 71.07 68.68 2.38 (22.07) 0.23
EORTC QLQ-BN20
Future uncertainty 29.66 31.63 -1.69 (21.42) 0.64
Visual disorder 15.44 23.95 -7.80 (18.89) 0.001
Motor dysfunction 22.60 23.08 0.10 (22.68) 0.80
Communication deficit 27.12 31.99 -4.87 (21.62) 0.08
Headaches 25.29 32.18 -5.95 (22.12) 0.02
Seizures 25.86 29.17 -1.82 (24.36) 0.38
Drowsiness 33.90 30.46 3.51 (27.95) 0.50
Hair loss 5.75 6.90 -1.19 (19.03) 0.59
Itchy skin 7.35 14.37 -7.02 (20.64) 0.02
Weakness legs 9.20 12.64 -4.76 (22.41) 0.18
Bladder control 12.43 21.26 -8.77 (24.01) 0.02
a Wilcoxon signed-rank test
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with mild AD, mild cognitive impairment, and elderly
controls, it was found that overall patient–proxy agreement
did not differ significantly between groups despite evident
differences in neurocognitive functioning [48]. In a related
study, patients with early AD generally reported a higher
HRQOL than their proxies, and discrepancies in patient–
Table 5 Mean difference
(patient-by-proxy minus
patient) cognitively intact
patients (n = 129)
SF-36 Scores Mean proxy Mean patient Mean difference
Mean (SD) p valuesa
Physical Component Summary 47.03 47.70 -0.79 (6.19) 0.77
Mental Component Summary 43.52 43.86 -0.04 (7.52) 0.66
Physical Functioning 87.98 89.82 -1.79 (13.73) 0.32
Mental health 74.07 76.07 -1.41 (18.33) 0.52
General health 63.79 65.67 -1.44 (20.90) 0.82
Role-physical 18.42 18.52 0.09 (9.85) 0.81
Bodily pain 83.53 85.91 -2.18 (24.22) 0.36
Vitality 65.07 66.72 -1.85 (21.28) 0.53
Role-emotional 21.65 20.60 1.03 (7.06) 0.11
Social functioning 85.16 84.10 1.02 (21.54) 0.64
EORTC QLQ-BN20 scores
Future uncertainty 22.06 19.87 2.26 (25.07) 0.67
Visual disorder 9.26 10.96 -1.71 (20.96) 0.22
Motor dysfunction 11.00 8.88 2.23 (15.87) 0.08
Communication deficit 17.78 19.84 -2.14 (25.96) 0.29
Headaches 26.60 21.13 5.50 (28.43) 0.06
Seizures 14.89 13.81 1.98 (23.49) 0.41
Drowsiness 18.77 17.26 0.98 (29.09) 0.75
Hair loss 7.05 7.81 -0.33 (17.86) 0.87
Itchy skin 9.80 9.01 0.67 (19.52) 0.72
Weakness legs 4.25 4.46 ﬃ0 (22.11) 0.99
Bladder control 6.09 5.95 -0.32 (19.52) 0.69
a Wilcoxon signed-rank test
Fig. 1 Bland–Altman plot
showing the range of agreement
with their 95 % limit for
physical component summary
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proxy ratings were associated with the presence of
anosognosia [49]. Although in the current study self-
awareness was not evaluated, we found that LGG patients
with cognitive deficits tended to report more tumor- and
treatment-related symptoms and thus a lower HRQOL.
This might indicate that potentially reduced self-awareness
can be associated with both higher and lower patient
HRQOL ratings relative to proxy ratings. There is currently
no consensus on the best way to deal with inconsistent
patient–proxy reports. While most methods rely on proxy
report as a ‘gold standard’ with patient–proxy concordance
taken as an indirect measure of patient (lack of) insight, the
accuracy of proxy reports bares critical examination when
the proxy is the caregiver. While the proxy-related factors
affecting patient–proxy discrepancies are largely unknown
in brain tumor patients, studies in patients with mild cog-
nitive impairment as a prodromal phase of AD, for
instance, have shown that caregivers’ cognitive skills and
educational level are significant predictors of the discrep-
ancies between caregiver ADL reports and directly asses-
sed patient performance on ADL [50]. Furthermore,
caregivers’ age, financial situation and valuation of life as a
whole [51], the type of caregiver, the perspective used [52],
caregiver burden [53], level of depression and anxiety [54],
and caregiver health may influence the accuracy of the
caregiver report. As stated earlier, patient-related factors
that might affect concordance between glioma patient and
proxy ratings include compromised mood and decreased
neurocognitive functioning [13, 14]. Interestingly, a study
that focused on screening for major depressive disorder in
glioma patients [55] did not find patient–proxy agreement
to be associated with severity of patient cognitive impair-
ment, although there was frequent disagreement between
glioma patients and proxies reports of depressive symp-
toms. A study that focused on the effect of neurocognitive
functioning and performance status (KPS) on patient–
proxy concordance [56] found patients and proxies to have
highly congruent assessments of symptom severity
regardless of patients’ neurocognitive functioning and
performance status. Use of proxies as a substitute for the
patient self-report of HRQOL should thus be treated with
caution, always taking into consideration the possibility of
potential bias.
A limitation of our study is the cross-sectional nature of
the data as opposed to longitudinal data or follow-up data
and generally mild neurocognitive problems in LGG
patients which did not allow the detection of small mean
differences between patient and patient-by-proxy ratings.
Follow-up data or assessment in high-grade glioma patients
with probably more neurocognitive problems might have
allowed the detection of small differences between patient
and patient-by-proxy HRQOL ratings. The percentage of
mean differences (equal or below 0, 5, and 10 points) could
be impacted by the number of possible scores on a scale
[12]. A very low number of possible scores or a very large
distance between two possible scores (i.e., [10 points)
could distort the agreement accuracy. Also, since patients
in this study had stable disease with mild neurocognitive
impairment, stable LGG are not representative of the
general brain tumor patient population. Investigating
agreement on high-grade glioma (HGG) patients with
severe neurocognitive impairment would provide
Fig. 2 Bland–Altman plot
showing the range of agreement
with their 95 % limit for
physical component summary
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additional information to assess agreement between patient
and patient-by-proxy ratings. The present study specifically
addressed HRQOL and did not include estimates of mood
or depression. Theoretically, mood might have affected our
outcomes to a certain extent as a study among patients with
major depression showed that responses to self-report
questionnaires are influenced by the presence of depression
[57].
One issue of potential concern is basing the analyses on
195 patients from the original sample of 281 patients might
result in bias. This might have been the case if patients who
did not participate in neurocognitive testing were excluded,
for instance, because of poor neurological or physical
status. We would argue, however, that it is unlikely that
bias was introduced in our study. At the time that we
conducted the original study, our expectation was that only
approximately 100 LGG patients would be alive in the
Netherlands and meet our eligibility criteria. In fact, we
were ultimately successful in identifying 281 eligible
patients. Because of limited financial and personnel
resources, we were only able to assess neurocognitive
functioning and HRQOL in 195 consecutive patients; we
assessed HRQOL only in the remaining 86 patients. There
was no evidence to suggest that those who underwent both
neurocognitive testing and completed HRQOL assessment
differed in any significant way from those who only
completed the questionnaires.
In conclusion, our data demonstrate that there is an
overall high level of agreement between patient and
patient-by-proxy ratings of LGG patients’ HRQOL,
although the agreement for some measures is weaker in
those cases where patients have neurocognitive impair-
ment. This implies that in general, patient-by-proxy-re-
ported outcomes can be used to replace missing patient-
reported outcomes to solve compliance issues in clinical
trials in this patient population. This is not the case, how-
ever, for patients with cognitive deficits who are no longer
able or willing to provide self-reported data. Specifically,
regarding the lack of a ‘gold standard,’ discordant patient–
proxy reports should currently be considered as a parallel
source of information on patient functioning. Since it is not
always possible to predict which patients will suffer from
progressive neurocognitive deficits, or when, it is advisable
to build proxy assessments into study designs from the start
of brain tumor clinical trials as is currently the case in
EORTC studies 26101 (NCT01290939) and 26091
(NCT01164189).
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